In a recent review of human cases, targeted therapy with a MEK or BRAF inhibitor or dual MEK/BRAF inhibitors used on histiocytic neoplasms has shown benefit to patients with and without a BRAFV600E variant, with treatments lasting over 6 months [46]. This evidence concerns the gene MAP2K7 and histiocytic neoplasm.